- Raw materials
- Anticoagulants
- Dermatan sulfate
Dermatan sulfate API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Dermatan sulfate | CAS No: 24967-94-0 | GMP-certified suppliers
A medication that supports anticoagulation and fibrinolysis by modulating blood coagulation pathways, primarily investigated for use in hematologic and thrombotic disorders.
Therapeutic categories
Product Snapshot
- Dermatan sulfate is formulated as an injectable solution for intramuscular administration
- It is primarily investigated for potential therapeutic applications in anticoagulation and wound healing
- The compound currently holds experimental status and has not received FDA or EMA approval
Clinical Overview
Dermatan sulfate has been investigated experimentally for its potential anticoagulant and antithrombotic effects, stemming from its capacity to interact with heparin cofactor II and modulate coagulation pathways. Its mechanism of action is related to the inhibition of thrombin activity, a key enzyme in the clotting cascade; however, its precise pharmacodynamics and clinical indications are not definitively established. The molecule's structural features contribute to binding affinity with various blood proteins, influencing fibrinolysis and cellular interactions.
Pharmacokinetic data related to absorption, distribution, metabolism, and excretion (ADME) of dermatan sulfate remain limited. Given its high molecular weight and polysaccharide nature, it is expected to be poorly absorbed via the oral route and primarily administered parenterally in experimental settings. Metabolic pathways likely involve enzymatic degradation by glycosidases and clearance via the reticuloendothelial system, though specific ADME parameters require further elucidation.
Safety and toxicity profiles have not been fully characterized in clinical contexts. As an experimental agent, dermatan sulfate's risk-benefit profile, potential adverse reactions, and contraindications remain to be systematically evaluated.
Currently, dermatan sulfate is not approved for therapeutic use in any major regulatory jurisdiction and has no widely recognized brand names. Its use is largely confined to research and investigational studies involving anticoagulation and related hematologic applications.
For API sourcing, it is essential to ensure dermatan sulfate of pharmaceutical-grade quality, characterized by well-defined molecular weight distribution, purity, and sulfation pattern. Suppliers should comply with current good manufacturing practices (cGMP) and provide comprehensive certificates of analysis to support regulatory submissions. Analytical methods to confirm identity, potency, and impurity profiles are critical for consistent quality in formulation development and experimental use.
Identification & chemistry
| Generic name | Dermatan sulfate |
|---|---|
| Molecule type | Small molecule |
| CAS | 24967-94-0 |
| UNII | J3OC7JVS54 |
| DrugBank ID | DB15880 |
Formulation & handling
- Dermatan sulfate is formulated exclusively for intramuscular injection in solution form, requiring sterile handling and injection protocols.
- As a small molecule with a high hydrophilicity (LogP -6.4), it is poorly permeable orally, supporting parenteral administration.
- Given its experimental status, stability and handling conditions must be validated to maintain potency and prevent degradation in aqueous injectable formulations.
Regulatory status
Dermatan sulfate is a type of Anticoagulants
Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.
There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.
Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.
While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.
In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.
